Navigation Links
Blame your parents for bunion woes
Date:5/19/2013

A novel study reports that white men and women of European descent inherit common foot disorders, such as bunions (hallux valgus) and lesser toe deformities, including hammer or claw toe. Findings from the Framingham Foot Studythe first to estimate the heritability of foot disorders in humansappear in Arthritis Care & Research, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).

Previous studies show that as many as 60% of older adults have foot disorders which may limit mobility and reduce their quality of life. In fact, bunions affect 23% of individuals 18 to 65 years of age and 36% of those over 65 years according to a study by Nix et al. While experts suggest that women, older adults and those with a higher body mass index (BMI) are at greater risk for foot disorders, there is little understanding of the genetics involved in their development.

The study, led by Arthritis Care & Research Editor-in-Chief, Dr. Marian Hannan from Hebrew SeniorLife and Harvard Medical School in Boston, Mass, included 1,370 participants enrolled in the Framingham Foot Study. Participants had a mean age of 66 years and 57% were female. Foot exams to identify hallux valgus, lesser toe deformities and plantar soft tissue atrophy were conducted between 2002 and 2008. The team estimated heritability using software that performs genetic analyses of familial data (pedigree structures).

Results show the prevalence of bunions, lesser toe deformities and plantar soft tissue atrophy was 31%, 30% and 28%, respectively. Hallux valgus and lesser toe deformity, two of the most common structural foot disorders that affect up to half of older adults in the U.S. and Europe, were found to be highly heritable depending on age and sex. The team reports that plantar soft tissue atrophy did not demonstrate significant heritability in the study cohort.

"Our study is the largest investigation of the heritability of co
'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Page: 1 2

Related biology news :

1. Gene sequencing project finds new mutations to blame for a majority of brain tumor subtype
2. Scientists conclude high fructose corn syrup should not be blamed for obesity
3. Viruses not to blame for chronic fatigue syndrome after all
4. Sick from stress? Blame your mom… and epigenetics
5. CU-Boulder study looks at microbial differences between parents, kids and dogs
6. Disappearing nannies force parents to accept their duties
7. Environment schemes for kids influence parents behavior
8. Parents talking to their teens about being overweight
9. Questionnaire completed by parents may help identify 1-year-olds at risk for autism
10. Parents seen as critical stakeholders in expanding newborn screening
11. Parents say that healthy eating is challenging for youth who play sports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... May 11, 2015  Through a well-rounded UAS delegation representing ... had a strong showing at AUVSI,s Unmanned 2015 conference last ... Ohio,s UAS industry met with over ... all points along the UAS ecosystem. "Our ... Vice President for Aerospace Rich Knoll . "If you ...
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... scientists have found that working together has its evolutionary roots ... of trials by scientists found that chimpanzees not only coordinate ... help a partner perform their role to achieve a common ... grapes out of a box. They had to work together ...
... common in modern warfare, often resulting in severe tissue ... according to the new research presented today at the ... Surgeons (AAOS). The Return to Run (RTR) program ... return high-level function to wounded warriors. It includes ...
... a majority of hip fracture patients of all ages and ... a new study presented today at the 2013 Annual Meeting ... whether or not living in a warm, sunny climate improves ... vitamin D levels of 1,539 patients, including 448 acute hip ...
Cached Biology News:Origins of human teamwork found in chimpanzees 2Origins of human teamwork found in chimpanzees 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... upcoming poster presentation at the International Society for ... for chronic Achilles tendinosis currently in a Phase ... May 29 th from 5:30 PM to ...
(Date:5/20/2015)... FRANCISCO, Calif. , May 20, 2015 /PRNewswire/ ... ) today presented preliminary data demonstrating the ability ... idiopathic pulmonary fibrosis (IPF) from other interstitial lung ... findings suggest the classifier,s potential to help thousands ... to resolve ambiguity in IPF diagnosis – a ...
(Date:5/20/2015)... May 19, 2015 Research and Markets ... "Global Cell Therapy Market Outlook 2020 " ... therapy in tissue and regenerative medicine is expected to ... options which could help in the growth of deregulated ... but they are unable to form new tissue or ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... (CTI),(Nasdaq and MTA: CTIC) announced today that the ... Letter") from the Listing,Qualifications Staff (the "Staff") of ... not comply with Marketplace Rule 4350(i)(1)(C) when the,Company ... ("SMI"),and issued additional common shares to SMI shareholders. ...
... 26 Cardium Therapeutics (NYSE Alternext US: CXM) today ... from the Company,s Board of Directors. The resignation ... "We thank Dr. Simon for his service to ... the years ahead," stated Christopher J. Reinhard, Chairman and ...
... Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 ... Per Share Increased 38 Percent to $3.90; Fourth Quarter ... $0.912009 Total Revenue Expected to be in the Range ... Expected to be in the Range of $4.55 to ...
Cached Biology Technology:Cell Therapeutics Receives Additional NASDAQ Notification 2Cell Therapeutics Receives Additional NASDAQ Notification 3Cell Therapeutics Receives Additional NASDAQ Notification 4Cardium Announces Retirement of Director 2Cardium Announces Retirement of Director 3Cardium Announces Retirement of Director 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 2Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 3Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 5Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 6Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 7Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 8Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 9Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 10Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 11Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 12Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 13Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 14Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 15Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 16Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 17Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 18Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 19Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 20Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 21Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 22Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 23Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 24Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 25Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 26Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 27
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Request Info...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Biology Products: